- $46.50m
- -$45.27m
- 16
- 46
- 35
- 23
Annual income statement for Passage Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 37.2 | 113 | 186 | 138 | 108 |
Operating Profit | -37.2 | -113 | -186 | -138 | -108 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -45.6 | -112 | -185 | -136 | -102 |
Provision for Income Taxes | |||||
Net Income After Taxes | -45.6 | -112 | -185 | -136 | -102 |
Net Income Before Extraordinary Items | |||||
Net Income | -45.6 | -112 | -185 | -136 | -102 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -45.6 | -112 | -185 | -136 | -102 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.16 | -2.91 | -3.48 | -2.5 | -1.77 |
Dividends per Share |